SCHEMBL3488952

SCHEMBL3488952

O=C1N(Cc2ccccc2)c2cc(Cl)cc(Cl)c2S(=O)(=O)N1Cc1ccccc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
MAPT P10636 7/20 0.41
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
LMNA P02545 2/20 0.36
F2 P00734 1/20 0.35
PLG P00747 1/20 0.35
ELANE P08246 1/20 0.35
CTSG P08311 1/20 0.35
CMA1 P23946 1/20 0.35
CTRC Q99895 1/20 0.35
TP53 P04637 1/20 0.35
ALDH1A1 P00352 2/20 0.34
ALDH2 P05091 2/20 0.34
ALDH3A1 P30838 2/20 0.34
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491856 0.90 MAPT (0.43) MAPTHCRTR1HCRTR2LMNAF2
SCHEMBL3489133 0.89 F2 (0.42) CA12MAPTHCRTR1HCRTR2LMNA
SCHEMBL3489746 0.87 MAPT (0.43) CA12MAPTHCRTR1HCRTR2LMNA
SCHEMBL3488910 0.87 CA12 (0.41) CA12MAPTHCRTR1HCRTR2LMNA
SCHEMBL3489625 0.87 CA12 (0.43) CA12CA2MAPTF2PLG
SCHEMBL3489294 0.85 CA12 (0.43) CA12MAPTLMNAF2PLG
SCHEMBL3489630 0.85 CA12 (0.43) CA12MAPTHCRTR1HCRTR2LMNA
SCHEMBL3489633 0.85 HCRTR2 (0.48) MAPTHCRTR1HCRTR2LMNATP53
SCHEMBL3489279 0.85 MAPT (0.42) CA12CA2MAPTHCRTR1HCRTR2
SCHEMBL3489424 0.85 CA12 (0.46) CA12CA2MAPTLMNAF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D CA12 4883/4885CA2 4878/4885MAPT 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.